晚期肝细胞癌伴大血管侵犯或转移性疾病的治疗:系统评价与荟萃分析
该系统评价与荟萃分析检索多个数据库至2016年2月15日,纳入14项研究(3项随机对照试验和11项观察性研究),评估索拉非尼、经动脉栓塞/化疗栓塞、钇-90/放疗、消融(或联合)及无治疗对晚期肝细胞癌伴大血管侵犯和/或肝外扩散患者的疗效。两项随机对照试验显示,在Child-Pugh A级肝功能的晚期肝细胞癌伴大血管侵犯和/或肝外扩散患者中,索拉非尼较最佳支持治疗一致改善总生存期(HR 0.66,95%CI 0.51-0.87;I²=0%)。
要点
- 在Child-Pugh A级肝功能的晚期肝细胞癌伴大血管侵犯和/或肝外扩散患者中,索拉非尼是唯一在随机研究中显示改善总生存期的治疗。
- 两项比较索拉非尼与最佳支持治疗的随机对照试验显示总生存期改善(HR 0.66,95%CI 0.51-0.87;I²=0%)。
- 支持其他治疗方式或用于Child-Pugh B级肝病患者的证据质量极低,缺乏高质量数据。
核心结论
- 在Child-Pugh A级肝功能的晚期肝细胞癌患者中,索拉非尼是唯一在随机研究中显示改善总生存期的治疗。
- 缺乏高质量数据支持其他治疗方式用于该人群或用于代偿较差(Child-Pugh B级)肝病患者。
研究设计与样本
- 系统评价与荟萃分析,检索多个数据库自建库至2016年2月15日,不限语言。
- 纳入14项研究,包括3项随机对照试验和11项观察性研究。
- 纳入研究比较索拉非尼、经动脉单纯栓塞/经动脉化疗栓塞、钇-90/放疗、消融(或联合)及无治疗。
主要发现
- 两项比较索拉非尼与最佳支持治疗的随机对照试验显示,在晚期肝细胞癌伴大血管侵犯和/或肝外扩散且Child-Pugh A级肝病患者中,总生存期一致改善(HR 0.66,95%CI 0.51-0.87;I²=0%)。
- 多项观察性研究评估了局部区域治疗单用或联合其他治疗,证据质量极低。
- 证据质量极低的情况适用于肝外扩散和(或)大血管侵犯患者。
关键数值与推荐
- 索拉非尼对比最佳支持治疗改善总生存期:HR 0.66(95%CI 0.51-0.87),I²=0%,基于2项随机对照试验,人群为晚期肝细胞癌伴大血管侵犯和/或肝外扩散且Child-Pugh A级肝病。
临床怎么用
- 对于Child-Pugh A级肝功能的晚期肝细胞癌伴大血管侵犯和/或肝外扩散患者,索拉非尼是随机研究中显示改善总生存期的治疗。
- 其他治疗方式在该人群或Child-Pugh B级肝病患者中的使用缺乏高质量数据支持。
局限性
- 支持其他治疗方式用于该人群或用于代偿较差(Child-Pugh B级)肝病患者的证据质量极低且缺乏高质量数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Hepatocellular carcinoma (HCC) is a complex disease most commonly arising in the background of chronic liver disease. In the past two decades, there has been a significant increase in our understanding of both the clinical and molecular heterogeneity of HCC. There has been a robust increase in clinical trial activity in patients with poor prognostic factors, such as macrovascular invasion and extrahepatic spread (EHS). We aimed to synthesize the evidence for the treatment of patients with advanced HCC based on these baseline characteristics, including patients with both Child-Pugh (CP) scores of A and B. A comprehensive search of several databases from each database inception to February 15, 2016 any language was conducted. We included 14 studies (three randomized controlled studies [RCTs] and 11 observational studies). We included studies that compared sorafenib, transarterial bland embolization/transarterial chemoembolization, yttrium-90/radiation therapy, ablation (or combination), and no therapy. Two RCTs comparing sorafenib to best supportive care demonstrated a consistent improvement in overall survival (OS) for patients with advanced HCC and metastatic vascular invasion (MVI) and/or EHS and CP A liver disease (hazard ratio, 0.66 [95% confidence interval, 0.51-0.87]; I2 = 0%). Several observational studies evaluated locoregional therapies alone or in combination with other treatments and were limited by very-low-quality of evidence. This was true for both patients with EHS and MVI. CONCLUSION: In patients with advanced HCC and CP A liver function, sorafenib is the only treatment that has been shown to improve OS in randomized studies. High-quality data supporting the use of other treatment modalities in this setting, or in the setting of patients with less compensated (CP B) liver disease, are lacking. (Hepatology 2018;67:422-435).
引用
- Finn RS, Zhu AX, Farah W, et al. Therapies for advanced stage hepatocellular carcinoma with macrovascular invasion or metastatic disease: A systematic review and meta-analysis. Hepatology. 2018. PMID: 28881497. doi:10.1002/hep.29486
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。